A detailed history of Summit Trail Advisors, LLC transactions in Galecto, Inc. stock. As of the latest transaction made, Summit Trail Advisors, LLC holds 25,000 shares of GLTO stock, worth $11,750. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,000
Holding current value
$11,750
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$0.6 - $0.89 $15,000 - $22,250
25,000 New
25,000 $19,000

Others Institutions Holding GLTO

About Galecto, Inc.


  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $11.9M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track This Portfolio

Track Summit Trail Advisors, LLC Portfolio

Follow Summit Trail Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Trail Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Trail Advisors, LLC with notifications on news.